Pharmaceuticals 2012, 5(8), 837-852; doi:10.3390/ph5080837
Review

Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases

* email and email
Received: 29 June 2012; in revised form: 2 August 2012 / Accepted: 15 August 2012 / Published: 17 August 2012
(This article belongs to the Special Issue Emerging Pain Targets and Therapy)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Transient receptor potential vanilloid 1 (TRPV1), a non-selective cation channel, is a receptor activated by high temperatures and chemical agonists such as the vanilloids and protons. Because of these properties, TRPV1 has emerged as a polymodal nocisensor of nociceptive afferent neurons. TRPV1 is thought to be a central transducer of hyperalgesia and a prime target for controlling pain pharmacologically because it is a point where many proalgesic pathways converge and it is upregulated and sensitized by inflammation and injury. However, whether TRPV1 agonists promote or inhibit inflammation remains unclear. We recently demonstrated that SA13353 (1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea), a novel TRPV1 agonist, inhibits tumor necrosis factor-a production by the activation of capsaicin-sensitive afferent neurons and reduces the severity of symptoms in kidney injury, lung inflammation, arthritis, and encephalomyelitis. These results suggest that TRPV1 agonists may act as anti-inflammatories in certain inflammatory and autoimmune conditions in vivo. Given the potential deleterious effects of inhibiting the population of channels with a protective function, caution should be taken in the use of potent TRPV1 antagonists as a general strategy to treat inflammation. Further studies are required to clarify the role of TRPV1 and neuropeptides, which are released because of TRPV1 activation in inflammation and autoimmune diseases.
Keywords: SA13353; transient receptor potential vanilloid 1; kidney injury; lung inflammation; autoimmune diseases; pain
PDF Full-text Download PDF Full-Text [140 KB, uploaded 17 August 2012 12:11 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Tsuji, F.; Aono, H. Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases. Pharmaceuticals 2012, 5, 837-852.

AMA Style

Tsuji F, Aono H. Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases. Pharmaceuticals. 2012; 5(8):837-852.

Chicago/Turabian Style

Tsuji, Fumio; Aono, Hiroyuki. 2012. "Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases." Pharmaceuticals 5, no. 8: 837-852.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert